Synapse - Works

Results (5608)

Novel mouse models of bladder cancer identify a prognostic signature associated with risk of disease progression

Journal Article

Park, S.; Rong, L.; Owczarek, T. B.; Di Bernardo, M.; Shoulson, R. L.; Chua, C. W.; Kim, J. Y.; Lankarani, A.; Chakrapani, P.; Syed, T.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)

Meeting Abstract

Morris, M. J.; De Bono, J. S.; Chi, K. N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Nordquist, L. T.; Vaishampayan, N.; El-Haddad, G.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Efficacy of avelumab + axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101

Meeting Abstract

Haanen, J.; Larkin, J.; Choueiri, T.; Albiges, L.; Rini, B.; Atkins, M.; Schmidinger, M.; Penkov, K.; Thomaidou, D.; Wang, J.; more...
Asia-Pacific Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Tazemetostat in combination with a PARP Inhibitor or checkpoint inhibitor in patients (Pts) with solid tumors

Meeting Abstract

Rudin, C. M.; Abida, W.; Spira, A.; Chadha, R.; Yang, J.; Powers, D.; Coleman, R.
Annals of Oncology (2021)

Fulltext@MSK | Save

Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)

Meeting Abstract

Rosenberg, J. E.; Galsky, M. D.; Balar, A. V.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Srinivas, S.; Drakaki, A.; Javery, A.; Nelson, B.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Rini, B. I.; Plimack, E. R.; Powles, T. B.; Voss, M. H.; Gurney, H. P.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Choueiri, T. K.
Annals of Oncology (2021)

Fulltext@MSK | Save

Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)

Meeting Abstract

Porta, C. G.; Motzer, R.; Ejzykowicz, F.; Blum, S. I.; Hamilton, M.; May, J. R.; Huo, S.; Kral, P.; Ivanescu, C.; Choueiri, T. K.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

Meeting Abstract

Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial

Meeting Abstract

Porta, C. G.; Burotto, M.; Suarez Rodriguez, C.; Bourlon, M. T.; Hsieh, J.; Shah, A. Y.; Hamzaj, A.; Bedke, J.; Pook, D.; Kessler, R.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)

Meeting Abstract

Rathkopf, D. E.; Decker, B.; Schum, P.; McBride, S.
Annals of Oncology (2021)

Fulltext@MSK | Save